441-30-5

Usage

Uses

Used in Pharmaceutical Industry:
N-(2,4-difluoro-6-nitrophenyl)acetamide is utilized as a potential anti-tuberculosis agent for its ability to inhibit the growth of Mycobacterium tuberculosis. This makes it a promising candidate for the development of new drugs to combat tuberculosis, a disease that continues to pose significant health challenges worldwide.
Used in Research Applications:
In the research field, N-(2,4-difluoro-6-nitrophenyl)acetamide serves as a valuable tool for studying the mechanisms of action against Mycobacterium tuberculosis. Its unique chemical structure, with the presence of both nitro and fluoro groups, allows researchers to explore various aspects of drug design and synthesis, potentially leading to the discovery of novel therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 399-36-0 N-(2,4-difluoro-phenyl)-acetamide 
• 364-30-7 2-amino-3,5-difluoronitrobenzene 
• 75-36-5 acetyl chloride 

Downstream Products

• 1025509-55-0 N₂-ethyl-3,5-difluoro-benzene-1,2-diamine 
• 191847-75-3 N-(2,4-difluoro-6-nitrophenyl)glycine methyl ester 
• 191847-69-5 N-(2,4-difluoro-6-nitrophenyl)glycine 
• 191847-66-2 N-cyanomethyl-2,4-difluoro-6-nitroaniline 
• 191847-81-1 5,7-difluoro-1H-benzimidazole 3-oxide 
• 364-30-7 2-amino-3,5-difluoronitrobenzene 

Relevant academic research and scientific papers

SAR study of clubbed [1,2,4]-triazolyl with fluorobenzimidazoles as antimicrobial and antituberculosis agents

In the present study, a series of novel 2-[4-(1H-[1,2,4]-triazol-1-yl)phenyl]-1-substituted-4,6-difluoro-1H-benz o[d]imidazole derivatives are synthesized by the alkylation of 2-[4-(1H-[1,2,4]-triazol-1-yl)phenyl]-4,6-difluoro-1H-benzo[d]imidazole with substituted alkyl and aryl halides. The compounds were evaluated for their preliminary in-vitro antibacterial activity against Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, and Salmonella typhosa and then were screened for their antitubercular activity against Mycobacterium tuberculosis H37Rv strain by broth microdilution assay method. The antibacterial data suggested that the analogs with electronegative substituents emerged as promising antimicrobials. It was also observed that the promising antimicrobials have proved to be better antimycobacterials. Few of selected analogs are under further evaluation for secondary antitubercular screening, as they have shown better activity compared to rifampin.

Synthesis, characterization, and antimicrobial activities of clubbed [1,2,4]-oxadiazoles with fluorobenzimidazoles

(Chemical Equation Presented) In this study, a novel series of substituted 4,6-difluoro-2-{2-[3-(substituted-phenyl)-[1,2,4]-oxadiazol-5-yl]-ethyl} -1H-benzo[d]imidazole derivatives were synthesized by condensation of 2,4-difluoro-6-nitrophenyl amine with 3-(substitutedphenyl-[1,2,4]-oxadiazol- 5yl) propionic acid by using 2,4,6-trichlorobenzoyl chloride in the presence of triethyl amine base. The compounds were evaluated for their preliminary in vitro antibacterial activity against Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, and Salmonella typhosa. The antibacterial data of the tested compounds indicated that most of the synthesized compounds showed moderate activity with reference standard Gentamycin.

HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY

The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.

Synthesis of substituted 2-ethoxycarbonyl- and 2-carboxyquinoxalin -3 ones for evaluation of antimicrobial and anticancer activity

A series of variously substituted quinoxalin-3-ones bearing an ethoxycarbonyl or carboxy group in the C-2 position has been prepared and their structures proved by 1H NMR spectroscopy. The obtained compounds were investigated in vitro for antimicrobial and anticancer activities. Preliminary results showed a moderate activity against a few strains of bacteria but no significant anticancer and anti-HIV activity.